Abstract
Many typescripts in this issue describe increasing use of HLA-haplotype-matched transplants in persons with leukaemia and report outcomes. Consequently, my goal is not to repeat these data but to focus on controversies and challenges relevant to this topic including: (1) what is the best technique for performing these transplants; (2) who is the best donor; (3) who should receive this type of transplant; (4) how do results compare with transplants from other donors; and (5) how can results be improved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Funding
Publication of this supplement was sponsored by Gilead Sciences Europe Ltd, Cell Source, Inc., The Chorafas Institute for Scientific Exchange of the Weizmann Institute of Science, Kiadis Pharma, Miltenyi Biotec, Celgene, Centro Servizi Congressuali, Almog Diagnostic.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gale, R.P. Controversies and challenges in HLA-haplotype-matched transplants for leukaemia. Bone Marrow Transplant 54 (Suppl 2), 719–720 (2019). https://doi.org/10.1038/s41409-019-0611-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-019-0611-4
- Springer Nature Limited